TAXUS

Related by string. Taxus * * Taxus stent . Boston Scientific Taxus . yew Taxus . TAXUS R . TAXUS stent . TAXUS Express . Taxus stents . TAXUS Stent . Taxus Express . TAXUS Element Stent . Taxus Stent . TAXUS p value . TAXUS Liberte . TAXUS ® . TAXUS Liberte stent . TAXUS Liberte Stent . Taxus Liberte . TAXUS Express Stent . TAXUS IV . TAXUS V . TAXUS Element Stent System . TAXUS ATLAS *

Related by context. All words. (Click for frequent words.) 76 TAXUS stent 72 CYPHER ® Stent 71 paclitaxel eluting stent 71 TAXUS Stent 70 CYPHER R Stent 70 TAXUS R 68 TAXUS Express 67 drug eluting stent 67 mm Stent 66 TAXUS Express Stent 66 Taxus Stent 66 TAXUS Liberte Stent 66 sirolimus eluting stent 65 XIENCE V 65 stent thrombosis 65 TAXUS ® 64 everolimus eluting stent 64 target lesion revascularization 64 XIENCE V PROMUS Stent 63 TAXUS Element Stent 63 TAXUS TM 63 XIENCE V demonstrated 63 Stent System 63 TAXUS Liberte 63 TAXUS VI 63 XIENCE V stent 62 TAXUS Liberte Long 62 XIENCE V vs. 62 drug eluting stents 62 TAXUS Liberte stent 62 CYPHER Stent 62 Coronary Stent 62 paclitaxel eluting coronary stent 62 SPIRIT III 62 zotarolimus eluting stent 61 TAXUS Liberté 61 Cypher Stent 61 binary restenosis 60 Coronary Stent System 60 CYPHER R Sirolimus eluting 60 diameter stenosis 60 MACCE 60 Taxus 60 angiographic outcomes 60 Endeavor stent 59 NEVO 59 TAXUS ATLAS 59 Tryton Side Branch 59 NEVO ™ 59 ischemic cardiomyopathy 59 definite stent thrombosis 59 stent DES 59 TAXUS p value 59 restenosis 59 TAXUS IV 59 TAXUS Express2 59 paclitaxel eluting 59 SPIRIT IV 59 sirolimus eluting stents 58 sirolimus stent 58 enoxaparin 58 stenting 58 segment binary restenosis 58 dual antiplatelet therapy 58 Endeavor drug eluting 58 events MACE 58 PROMUS 58 ACTEMRA 58 angiographic 58 stent restenosis 58 Events MACE 58 Long Lesion 58 acute coronary syndromes 58 Atom Stent 58 ENDEAVOR clinical 57 Sirolimus eluting Coronary Stent 57 active comparator 57 TAXUS V 57 repeat revascularization 57 ticagrelor 57 RE LY 57 carotid stenting 57 paclitaxel eluting stents 57 Xience 57 PROMUS Element Stent 57 PROMUS Element 57 PROMUS ® 57 stable angina 57 everolimus eluting stents 57 drug eluting stent DES 57 everolimus 57 Sirolimus Eluting Coronary Stent 57 CYPHER ® Sirolimus eluting 57 sirolimus eluting 57 ZoMaxx 57 nonrandomized 57 MitraClip 57 target vessel revascularization 57 CYPHER ® 57 Taxus stent 56 stent thromboses 56 SPIRIT FIRST 56 NEVO TM 56 rivaroxaban 56 NYHA Class II 56 ARCOXIA 56 XIENCE TM 56 stent implantation 56 fondaparinux 56 TAXUS Liberté stent 56 ipsilateral stroke 56 bosentan 56 Major Adverse Cardiac 56 XIENCE V Everolimus Eluting 56 stent 56 valsartan 56 Xience V 56 fenofibrate 56 ENDEAVOR II 56 acute coronary syndrome 56 Impella 56 tolvaptan 56 composite endpoint 56 de novo lesions 56 Resolute DES 56 reintervention 56 telmisartan 56 carotid artery stenting 56 plus dexamethasone 55 elagolix 55 virologic response 55 Liberte TM 55 nondiabetic patients 55 acute coronary syndromes ACS 55 bivalirudin 55 drug eluting coronary stent 55 CUSTOM III 55 fully bioabsorbable 55 workhorse lesions 55 myocardial infarction MI 55 Val HeFT 55 SYNTAX trial 55 ABSORB trial 55 TRITON TIMI 55 teriflunomide 55 non valvular atrial 55 carotid stent 55 failure TVF 55 reinfarction 55 PROMUS R 55 decitabine 55 drug eluting coronary stents 55 LVEF 55 oral diclofenac 55 acute myocardial infarction AMI 55 TAVI 55 myocardial infarction 55 adalimumab 55 candesartan 55 eculizumab 55 cardiovascular hospitalization 55 MADIT II 55 Taxus Express 55 severe aortic stenosis 55 eptifibatide 55 placebo controlled clinical 55 Betaferon ® 55 Drug eluting stent 55 Median survival 55 Drug Eluting Stents 55 CYPHER R Sirolimus Eluting 55 PROMUS Element Everolimus Eluting 55 unfractionated heparin 54 Resolute drug eluting 54 pioglitazone 54 ENDEAVOR IV 54 plus gemcitabine 54 RE LY ® 54 eplerenone 54 Express2 TM paclitaxel eluting 54 BRIM2 54 prospective multicenter 54 zotarolimus 54 multicentre randomized 54 Pivotal Trial 54 Cordis Cypher 54 thrombotic events 54 PERSEUS 54 Taxus Liberte stent 54 atrial fibrillation AF 54 CYPHER 54 IIIa inhibitor 54 prospective randomized controlled 54 Dr. Kandzari 54 ximelagatran 54 Taxus Liberte 54 apixaban 54 patency 54 coronary revascularization 54 ™ Everolimus Eluting 54 phase IIa clinical 54 secondary endpoint 54 Rivaroxaban 54 non inferiority 54 revascularization 54 posaconazole 54 ACTEMRA TM 54 patients undergoing percutaneous 54 nesiritide 54 peginterferon alfa 2b 54 Target Lesion Revascularization TLR 54 FOLPI 54 CLARITY study 54 XIENCE 54 bypass graft CABG surgery 54 Everolimus Eluting Coronary Stent 54 DAPT 54 prospective randomized 54 noninferiority 54 Boston Scientific Taxus 54 EVEREST II 54 octreotide LAR 54 endovascular repair 54 acute ischemic stroke 54 Drug Eluting Stent 54 carotid artery stenting CAS 54 bifurcation lesions 54 irbesartan 54 platinum chromium alloy 54 Amrubicin 54 cardiac resynchronization therapy 54 cardiovascular hospitalizations 54 CYPHER R 54 Endeavor Resolute 54 Paclitaxel Eluting Coronary Stent 54 Valsartan 54 thromboembolic 54 ABSORB 54 Stent thrombosis 54 Genous stent 54 ACUITY trial 54 systemic embolism 54 Eluting Coronary Stent System 54 bioabsorbable stent 54 venous thromboembolism 54 Edwards SAPIEN valve 54 transfemoral 54 STENT 54 clopidogrel 53 degarelix 53 multicenter 53 brivaracetam 53 percutaneous intervention 53 tolerability 53 vertebral fractures 53 TAXUS Express2 Paclitaxel Eluting 53 vandetanib 53 PRECiSE 53 TM Drug Eluting 53 HUMIRA 53 Express2 TM Paclitaxel Eluting 53 placebo controlled Phase 53 TAXUS drug eluting 53 dronedarone 53 angiographic restenosis 53 SYNTAX 53 ATACAND 53 rFVIIa 53 Stent Thrombosis 53 Vascular Wrap 53 #mg BID [001] 53 ST elevation myocardial 53 tiotropium 53 defibrillator CRT D 53 chlorambucil 53 PEG INTRON 53 prospective multicenter randomized 53 paroxysmal AF 53 ezetimibe simvastatin 53 HORIZONS AMI trial 53 oral FTY# 53 Targretin 53 afatinib 53 XIENCE PRIME 53 cerebrovascular events 53 primary patency 53 multicenter prospective 53 TM Everolimus Eluting 53 ADHF 53 V Everolimus Eluting Coronary 53 glufosfamide 53 MACUGEN 53 morphometric vertebral fractures 53 Hazard Ratio 53 Angiomax 53 FOLFOX4 53 vessel renarrowing 53 stent BMS 53 antiplatelet therapy 53 randomized multicenter 53 coronary artery disease 53 R Paclitaxel Eluting 53 pegylated interferon alfa 2b 53 anti arrhythmic drug 53 Phase IIIb 53 CUSTOM II 53 acute decompensated heart 53 uncoated stent 53 XGEVA 53 Xience Prime 53 vertebral fracture 53 tirofiban 53 sustained virological response 53 myocardial infarction stroke 53 thromboembolic events 53 Multaq R 53 receiving golimumab 53 FOLFOX 53 Restenosis 53 CABG 53 NEVO RES 53 COPAXONE R 53 Taxus Element 52 mg QD 52 paclitaxel 52 LymphoStat B 52 CRT Ds 52 carboplatin paclitaxel 52 multivessel disease 52 CANCIDAS 52 TAXUS Element Paclitaxel Eluting 52 NATRECOR R 52 SVR# 52 DMARD 52 atherothrombotic events 52 TAXUS Element 52 FFR guided treatment 52 coronary stent 52 Nitinol Stent 52 recurrent GBM 52 GORE VIABAHN Endoprosthesis 52 randomized controlled clinical trials 52 Acute Myocardial Infarction 52 TAXUS Express2 paclitaxel eluting 52 clopidogrel Plavix ® 52 ARIXTRA 52 atherothrombotic disease 52 unstable angina pectoris 52 oxycodone CR 52 DU #b 52 randomized clinical trials 52 Acute Coronary Syndrome 52 plus prednisone 52 Multicenter Automatic Defibrillator Implantation 52 telcagepant 52 Protelos 52 elotuzumab 52 PROMUS TM 52 placebo controlled 52 placebo dexamethasone 52 TAVR 52 SYNERGY Stent 52 PFO closure 52 RESOLUTE 52 reblockage 52 multicenter randomized 52 median PFS 52 Taxus Liberté 52 primary endpoint 52 Hycamtin ® 52 stent binary restenosis 52 functional mitral regurgitation 52 Atacand 52 STRIDE PD 52 Stenting 52 perindopril 52 zoledronic acid 52 XELOX 52 cardiac resynchronization 52 tapentadol ER 52 APPRAISE 52 eluting stent 52 ONTARGET 52 phase IIb clinical 52 MADIT CRT trial 52 phase IIIb 52 palonosetron 52 ramipril 52 Express2 52 Drug Eluting Stent System 52 STEMI patients 52 MitraClip R 52 MYDICAR ® 52 randomized Phase III 52 MitraClip device 52 revascularizations 52 lopinavir r arm 52 sirolimus 52 alvimopan 52 revascularisation 52 lumbar spine BMD 52 certolizumab pegol 52 Free Survival PFS 52 carotid endarterectomy 52 eluting stents 52 pain palliation 52 olmesartan 52 rosuvastatin 52 peginterferon alfa 2a 52 endophthalmitis 52 zalutumumab 52 Stent 52 catheter occlusion 52 belimumab 52 carotid endarterectomy CEA 52 neurologic progression 52 azacitidine 51 CIMZIA ™ 51 secondary efficacy endpoints 51 BioMatrix 51 ischemia driven 51 tocilizumab 51 pomalidomide 51 angiotensin receptor blocker ARB 51 TACE 51 stenoses 51 undergoing coronary artery 51 TAXUS Express Atom Stent 51 CIMZIA TM 51 sustained virologic response 51 relapsing multiple sclerosis 51 prespecified 51 endarterectomy 51 STELARA 51 metaglidasen 51 nonvertebral fractures 51 nonfatal MI 51 Medtronic Endeavor 51 ischemic 51 NLX P# 51 CYCLOSET 51 recurrent GBM patients 51 idraparinux 51 CYPHER R stent 51 vinorelbine 51 PRIMO CABG2 51 pegylated liposomal doxorubicin 51 GORE TAG Device 51 Tavocept 51 Median PFS 51 cangrelor 51 Phase 2b study 51 levosimendan 51 ENDEAVOR 51 thrombolytic agents 51 SEROQUEL 51 Randomized Evaluation 51 coronary intervention 51 PROMACTA 51 TM Paclitaxel Eluting 51 ToGA 51 ACCORD Lipid 51 VELCADE melphalan 51 multicenter clinical 51 placebo controlled Phase III 51 evaluating REVLIMID 51 QTc 51 severe psoriasis 51 free survival PFS 51 mg kg dose 51 pazopanib 51 candesartan cilexetil 51 Endeavor DES 51 deferiprone 51 plus GP IIb 51 cardiovascular morbidity 51 ExTRACT TIMI 51 dalteparin 51 patients undergoing CABG 51 Ventavis 51 dabigatran etexilate 51 IV NSCLC 51 Angiographic 51 Cypher Sirolimus 51 complete cytogenetic response 51 fenofibric acid 51 complete cytogenetic 51 docetaxel chemotherapy 51 sorafenib Nexavar 51 statin 51 coronary stenting 51 axitinib 51 Percutaneous Coronary Intervention 51 ENDEAVOR III 51 Patency 51 nab paclitaxel 51 icatibant 51 MADIT CRT 51 graft occlusion 51 INTEGRILIN 51 symptomatic VTE 51 certolizumab 51 NSTE ACS 51 CRESTOR #mg 51 MULTI LINK VISION 51 TAXUS Element Stent System 51 MERLIN TIMI 51 antiplatelet agent 51 periprocedural 51 mycophenolate mofetil 51 randomized clinical 51 Sapien valve 51 EchoCRT 51 ABC/3TC 51 coronary interventions 51 temsirolimus 51 ocrelizumab 51 LCP AtorFen 51 aldosterone antagonists 51 drug coated Taxus 51 NOXAFIL 51 dapagliflozin 51 vertebral compression fractures 51 Taxotere ® 51 EuroPCR 51 Kaplan Meier analysis 51 PTNS 51 ReoPro 51 PICSO ® 51 interferon beta 1b 51 Platinum Chromium 51 virologic failure 51 coronary drug eluting 51 events AEs 51 Myocardial Infarction Study 50 ULORIC 50 RoACTEMRA 50 abciximab 50 randomized trials 50 FROVA 50 TAXUS Liberte paclitaxel eluting 50 Bare Metal Stents 50 FOLFIRI 50 plus ribavirin 50 ID TLR 50 coronary lesions 50 STEMI 50 Combo Stent 50 GP IIb IIIa inhibitor 50 Acute Coronary Syndromes 50 chemoradiotherapy 50 lacosamide 50 desvenlafaxine succinate 50 renarrowing 50 GAMMAGARD 50 CABG surgery 50 noninferior 50 amrubicin 50 REBETOL 50 Arixtra 50 Coronary Artery Bypass Graft 50 ibandronate 50 OLYMPIA registry 50 metastatic HRPC 50 LMWH 50 unfractionated heparin UFH 50 romiplostim 50 Clinical Outcomes Utilizing Revascularization 50 perioperative mortality 50 Medtronic Endeavor stent 50 oral Xeloda 50 EverFlex 50 IN.PACT Falcon 50 evaluable 50 REYATAZ r 50 HbA1c levels 50 randomized controlled clinical 50 rosuvastatin #mg 50 interferon beta therapy 50 Aromasin 50 neointimal hyperplasia 50 discontinuations 50 prasugrel 50 5-FU/LV 50 CIMZIA TM certolizumab pegol 50 multicenter multinational 50 Phase 2b clinical 50 ularitide 50 cytogenetic response 50 percutaneous coronary intervention 50 GP IIb IIIa inhibitors 50 pharmacokinetic characteristics 50 tolerability profile 50 EURIDIS 50 simvastatin ezetimibe 50 bevacizumab 50 NATRECOR ® 50 cardiac resynchronisation therapy 50 PSADT 50 colesevelam HCl 50 dose regimens 50 Cotavance 50 TMC# r 50 plus methotrexate 50 randomized 50 death reinfarction 50 stented 50 serum phosphorus 50 Stenting Trial CREST 50 atheroma volume 50 infarction STEMI 50 transcatheter aortic valve implantation 50 PRECISE 50 ruboxistaurin 50 stents 50 trials RCTs 50 cinacalcet 50 STARFlex R 50 fluvastatin 50 Vascugel ® 50 octreotide 50 amiodarone 50 lamivudine monotherapy 50 sunitinib malate 50 preventing restenosis 50 everolimus eluting 50 onset atrial fibrillation 50 amlodipine 50 custirsen 50 etanercept 50 stents BMS 50 clodronate 50 dose cohorts 50 LVAS 50 DASISION 50 anastrozole 50 SCD HeFT 50 mcg albinterferon alfa 2b 50 ICD implants 50 Rosuvastatin 50 Carotid Revascularization Endarterectomy vs. 50 gemcitabine 50 methylnaltrexone 50 Rasilez Tekturna 50 Instanyl 50 EDEMA3 50 AneuRx 50 OMNARIS Nasal Spray 50 sunitinib 50 NYHA Class III 50 goserelin 50 RGT arm 50 nilotinib 50 Operative mortality 50 Doxil ® 50 Entereg 50 insulin glargine 50 statin therapy 50 low dose Iluvien 50 docetaxel 50 Catena ® 50 cediranib 50 TMC# [001] 50 eltrombopag 50 standard chemotherapy regimen 50 pCR 50 evaluating CK # 50 Bivalirudin 50 discontinuations due 50 REMICADE ® 50 acute myocardial infarction 50 Abbott bioabsorbable everolimus eluting 50 nicardipine 50 TAXUS paclitaxel eluting coronary 50 drug eluting balloons 50 metastatic renal cell carcinoma 50 coated stent 50 IFN alfa 50 revascularization procedures 50 NYHA class 50 graft patency 50 Cypher stent 50 relapsed refractory multiple myeloma 50 evaluating tivozanib 50 recurrent VTE 50 PEGylated interferon beta 1a 50 Stents 50 Angiox R 50 PRoFESS 50 CYPHER SELECT TM 50 YERVOY 50 rehospitalization 50 Ereska 50 Zilver PTX 50 telaprevir dosing 50 plus glycoprotein IIb 50 subtrochanteric 50 Abbott XIENCE V 50 pertuzumab 50 lipid lowering therapy 50 ribavirin RBV 50 NEXIUM 50 thrombolysis 50 antiarrhythmic drugs 49 CoFactor 49 antithrombotics 49 Angiox 49 MACE 49 clopidogrel Plavix 49 pramlintide 49 Bare Metal Stent 49 recurrent stroke 49 prospectively defined 49 aspirin clopidogrel 49 TORISEL 49 esomeprazole 49 eluting coronary stent 49 insulin detemir 49 embolic protection 49 pioglitazone Actos 49 antiplatelet agents 49 Destination Therapy 49 refractory angina 49 ancrod 49 ACTOS 49 AIM HIGH 49 resynchronization therapy 49 thrombus aspiration 49 balloon kyphoplasty 49 thromboembolism 49 PRADAXA 49 COPEGUS 49 renal artery stenting 49 vicriviroc 49 oral allopurinol 49 Edge STudy 49 doxorubicin docetaxel 49 doxorubicin 49 teriparatide 49 ambrisentan 49 LUX Lung 49 beta blocker therapy 49 MoxDuo TM IR 49 left ventricular dysfunction 49 losartan 49 overlapping stents 49 Celacade 49 gefitinib 49 MULTI LINK 49 Torisel 49 vildagliptin 49 demonstrated clinically meaningful 49 NT proBNP 49 COMFORT II 49 prospective multicentre 49 PAOD 49 invasive candidiasis 49 oral anticoagulant 49 CARE HF 49 HoFH 49 peripheral arterial disease 49 Self Expanding Stent 49 VIDAZA 49 ISENTRESS 49 pemetrexed 49 Acute Ischemic Stroke 49 carotid stents 49 ACE inhibitor 49 mg BID 49 muraglitazar 49 multicenter Phase III 49 MabCampath 49 Evicel 49 Phase #/#a 49 Taxotere R 49 antiplatelet drugs 49 atorvastatin 49 allopurinol 49 riociguat 49 MGuard 49 pharmacokinetic PK 49 double blinded randomized 49 cobalt chromium stent 49 TELCYTA 49 multicenter Phase 49 tumor shrinkage 49 cardiac toxicity 49 ePTFE graft 49 paclitaxel stent 49 COPAXONE ® 49 carotid IMT 49 PASI scores 49 peginterferon alfa 2a #KD 49 TAXUS Liberte Atom Stent 49 cardiovascular mortality 49 pimecrolimus cream 49 CYPHER stent 49 IRESSA 49 CombAT 49 mitral regurgitation 49 rosiglitazone 49 microvascular complications 49 picoplatin 49 ARB telmisartan 49 imetelstat 49 Chrysalin 49 Vernakalant 49 dacarbazine 49 endoleaks 49 multicenter randomized placebo controlled 49 TAXUS stents 49 biochemical recurrence 49 HBeAg negative patients 49 Cypher drug eluting 49 letrozole 49 olanzapine 49 drug coated stents 49 randomized controlled 49 alemtuzumab 49 aldosterone antagonist 49 Endeavor Drug Eluting 49 stent grafts 49 dose escalation Phase 49 cilostazol 49 bioabsorbable drug eluting 49 olaparib 49 drug zotarolimus 49 label multicenter 49 macrovascular 49 circulating EPCs 49 antithrombotic therapies 49 NAVISTAR R 49 evaluable patients 49 PRIMO CABG 49 VTE 49 lupus nephritis 49 KRAS mutations occur 49 STARFlex ® 49 Phase IIb clinical 49 Phase IIB 49 multicenter randomized controlled 49 PEG Intron 49 Rebif ® 49 dose atorvastatin 49 FTY# 49 infliximab 49 pitavastatin 49 Xelox 49 sunitinib Sutent 49 Dacogen injection 49 patients evaluable 49 peginterferon 49 OPCAB 49 Candesartan 49 saphenous vein grafts 49 Medtronic stent 49 opioid induced bowel dysfunction 49 lymphadenectomy 49 Phase Ib clinical 49 pantoprazole 49 Liberte stent 49 DEFINITY ® 49 anticoagulation 49 LEXIVA r 49 CA4P 49 nonfatal myocardial infarction 49 lispro 49 macrovascular disease 49 BENICAR HCT 49 clazosentan 49 MYDICAR 49 ivabradine 49 Pioglitazone 49 Zometa 49 Fludara 49 Medtronic CoreValve 49 percutaneous coronary interventions 49 myocardial ischemia 49 HeFH 49 glycated hemoglobin levels 49 unstable angina UA 49 hemodialysis patients 49 SEROQUEL R 49 MTWA 49 MGuard ™ 49 β blockers 49 atrasentan 49 Heparin Bioactive Surface 49 VICTRELIS 49 lipid lowering agents 49 bronchial thermoplasty 49 randomized blinded 49 crizotinib PF # 49 Eluting Stent 49 MIRCERA 49 superficial femoral 49 ADX# 49 antiarrhythmic drug 49 antihypertensive therapy 49 Randomized Study 49 oncologic outcomes 49 Thrombolysis 49 carotid artery disease 49 recurrent ischemia 49 placebo controlled trials 49 gout flares 49 dosing regimens 49 NSABP C 49 Peg IFN 49 MICARDIS ® 49 tanespimycin 48 SCH # 48 undetectable HBV DNA 48 bare metal 48 multicentre 48 locoregional recurrence 48 dosing cohorts 48 glycoprotein IIb IIIa inhibitor 48 hypercholesterolemia 48 infusional 5-FU/LV 48 receiving VICTRELIS 48 Aortic Stenosis 48 thromboprophylaxis 48 EndoBarrier 48 transcatheter 48 HuMax EGFr 48 tumor recurrence 48 VESTAsync 48 stent graft 48 AVANDIA 48 Endoprosthesis 48 dose dexamethasone 48 thinner struts 48 IIIa inhibitors 48 primary hypercholesterolemia 48 Neulasta R 48 AIR CF2 48 APTIVUS 48 dose escalation 48 ASA# 48 VAPRISOL 48 plus COPEGUS 48 tumor lysis syndrome 48 FOSRENOL R 48 Heart Valve 48 Myocardial Infarction 48 CCyR 48 mg BID dose 48 comparator arm 48 endovascular therapy 48 e HEALING 48 PARTNER Trial 48 interferon alfa 48 nonobstructive CAD 48 Taxotere 48 Sideguard 48 Xience stent 48 VADT 48 subanalysis 48 febrile neutropenia 48 mg dose 48 sipuleucel T 48 naïve HCV 48 comparing XIENCE V 48 achieved statistical significance 48 angiotensin converting enzyme inhibitor 48 VT VF 48 disease progression 48 cryptogenic stroke 48 annualized relapse 48 Endovascular Valve Edge 48 intravitreal injection 48 mitoxantrone 48 Telmisartan 48 peripheral stent 48 neovascular AMD 48 angiographic follow 48 venous thromboembolic events 48 neointimal 48 bivalirudin monotherapy 48 Phase 2b 48 infarct size 48 placebo p = 48 HBeAg seroconversion 48 L PPDS 48 uncoated stents 48 tecarfarin 48 HCV RESPOND 2 48 mCi kg 48 Phase 2a clinical 48 Pegasys ® 48 vernakalant 48 ROCKET AF 48 valvular disease 48 EDEMA4 trial 48 REMINYL ® 48 TAXUS paclitaxel eluting stent 48 VELCADE 48 Catheter ablation

Back to home page